285 related articles for article (PubMed ID: 23187853)
1. Vaccines for pancreatic cancer.
Soares KC; Zheng L; Edil B; Jaffee EM
Cancer J; 2012; 18(6):642-52. PubMed ID: 23187853
[TBL] [Abstract][Full Text] [Related]
2. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
Blair AB; Zheng L
Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for pancreatic ductal adenocarcinoma.
Carpenter E; Nelson S; Bednar F; Cho C; Nathan H; Sahai V; di Magliano MP; Frankel TL
J Surg Oncol; 2021 Mar; 123(3):751-759. PubMed ID: 33595893
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma.
Schmiechen ZC; Stromnes IM
Front Immunol; 2020; 11():613815. PubMed ID: 33584701
[TBL] [Abstract][Full Text] [Related]
5. Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer.
Koido S; Okamoto M; Shimodaira S; Sugiyama H
Immunotherapy; 2016 Nov; 8(11):1309-1320. PubMed ID: 27993090
[TBL] [Abstract][Full Text] [Related]
6. Novel pancreatic cancer vaccines could unleash the army within.
Springett GM
Cancer Control; 2014 Jul; 21(3):242-6. PubMed ID: 24955709
[TBL] [Abstract][Full Text] [Related]
7. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
Ibrahim AM; Wang YH
World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
[TBL] [Abstract][Full Text] [Related]
8. Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.
Balachandran VP; Beatty GL; Dougan SK
Gastroenterology; 2019 May; 156(7):2056-2072. PubMed ID: 30660727
[TBL] [Abstract][Full Text] [Related]
9. Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer.
Kajihara M; Takakura K; Kanai T; Ito Z; Matsumoto Y; Shimodaira S; Okamoto M; Ohkusa T; Koido S
World J Gastroenterol; 2016 May; 22(18):4446-58. PubMed ID: 27182156
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
Sahin IH; Askan G; Hu ZI; O'Reilly EM
Ann Oncol; 2017 Dec; 28(12):2950-2961. PubMed ID: 28945842
[TBL] [Abstract][Full Text] [Related]
11. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation.
Lutz E; Yeo CJ; Lillemoe KD; Biedrzycki B; Kobrin B; Herman J; Sugar E; Piantadosi S; Cameron JL; Solt S; Onners B; Tartakovsky I; Choi M; Sharma R; Illei PB; Hruban RH; Abrams RA; Le D; Jaffee E; Laheru D
Ann Surg; 2011 Feb; 253(2):328-35. PubMed ID: 21217520
[TBL] [Abstract][Full Text] [Related]
12. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi M; Bartholin L; Neuzillet C
World J Gastroenterol; 2018 May; 24(20):2137-2151. PubMed ID: 29853732
[TBL] [Abstract][Full Text] [Related]
13. Challenges and Opportunities for Pancreatic Cancer Immunotherapy.
Bear AS; Vonderheide RH; O'Hara MH
Cancer Cell; 2020 Dec; 38(6):788-802. PubMed ID: 32946773
[TBL] [Abstract][Full Text] [Related]
14. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk.
Orozco CA; Martinez-Bosch N; Guerrero PE; Vinaixa J; Dalotto-Moreno T; Iglesias M; Moreno M; Djurec M; Poirier F; Gabius HJ; Fernandez-Zapico ME; Hwang RF; Guerra C; Rabinovich GA; Navarro P
Proc Natl Acad Sci U S A; 2018 Apr; 115(16):E3769-E3778. PubMed ID: 29615514
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for pancreatic cancer: A 2020 update.
Schizas D; Charalampakis N; Kole C; Economopoulou P; Koustas E; Gkotsis E; Ziogas D; Psyrri A; Karamouzis MV
Cancer Treat Rev; 2020 Jun; 86():102016. PubMed ID: 32247999
[TBL] [Abstract][Full Text] [Related]
16. Significance of Wilms' tumor 1 antigen as a cancer vaccine for pancreatic cancer.
Koido S; Okamoto M; Kobayashi M; Shimodaira S; Sugiyama H
Discov Med; 2017 Aug; 24(130):41-49. PubMed ID: 28950074
[TBL] [Abstract][Full Text] [Related]
17. Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer).
Yoshimura K; Olino K; Edil BH; Schulick RD; Oka M
Surg Today; 2010 May; 40(5):404-10. PubMed ID: 20425541
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic ductal adenocarcinoma: a review of immunologic aspects.
Wachsmann MB; Pop LM; Vitetta ES
J Investig Med; 2012 Apr; 60(4):643-63. PubMed ID: 22406516
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reaction.
Tanemura M; Miyoshi E; Nagano H; Eguchi H; Matsunami K; Taniyama K; Hatanaka N; Akamatsu H; Mori M; Doki Y
World J Gastroenterol; 2015 Oct; 21(40):11396-410. PubMed ID: 26523105
[TBL] [Abstract][Full Text] [Related]
20. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma.
Zheng L; Xue J; Jaffee EM; Habtezion A
Gastroenterology; 2013 Jun; 144(6):1230-40. PubMed ID: 23622132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
